Arrowhead Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies that address intractable diseases through gene silencing technologies. Utilizing a comprehensive array of RNA chemistries, Arrowhead's treatments leverage the natural mechanism of RNA interference (RNAi) to inhibit the expression of specific genes associated with disease. The company aims to provide innovative drugs for genetic disorders characterized by abnormal protein overproduction. With a focus on expanding the applicability of RNAi beyond the liver, Arrowhead's clinical and preclinical pipelines target a variety of therapeutic areas. Headquartered in Pasadena, California, and supported by research and development teams in Madison, Wisconsin, and San Diego, California, Arrowhead fosters a collaborative and science-driven environment where employees work together to bring transformative therapies to patients in need.